Yes, but they are weighed differently. Investors and their counsel look at whether the pending claims are likely to grant and whether they cover the current product. A provisional with no follow-on filing, or claims drafted around a prototype no longer in production, adds little.
We use essential cookies to make our site work. 🍪 With your consent, we may also use non-essential cookies to improve user experience and analyze website traffic. By clicking “Accept,” you agree to our website's cookie use as described in our Cookie Policy. You can change your cookie settings at any time by clicking “Preferences.”